Introduction
Depression symptoms are common for older adults with memory difficulties and their caregivers. Mindfulness‐based cognitive therapy (MBCT) reduces the risk of relapse in recurrent depression and improves depression symptoms. We explored recruitment and retention success and preliminary effect sizes of MBCT on depression and anxiety symptoms, as well as mindfulness facets, in individuals with memory difficulties and their caregivers.
Methods
A difficulty with memory group (DG) and caregiver group (CG) were randomized into either the MBCT intervention or waitlist control. After serving as controls, participants received the intervention. Mean pre–post changes by group were compared and effect sizes computed. Correlations between mindfulness facets and depression symptoms are also presented.
Results
Only 47% of the initial participants completed the study. The intervention did not have an effect on the outcome variables examined. However, improvements in non‐judgmental scores were associated with reductions in the number of depression symptoms reported by DG participants (r = –0.90, 95% confidence interval [CI]: –0.98, –0.52) and CG participants (r = –0.76, 95% CI: –0.95, –0.19). Furthermore, improvements in awareness scores (r = –0.69, 95% CI: –0.93, –0.05) and level of burden (r = 0.87, 95% CI: 0.49, 0.97) also significantly correlated with reduced depression symptoms in the CG group.
Conclusions
By determining preliminary MBCT effect sizes in individuals with memory difficulties and their caregivers, research with larger, controlled samples is now justified to determine the true effects of MBCT in these populations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.